

8 December 2022



The Nifty previous session ended 0.26% up at 18609.35. It opened on a flat note and remained range-bound throughout the session towards ending on subdued note. Chart pattern suggesting pullback towards critical resistances may again find sellers. Hence, staying cautious on rise around 18800 levels is advised. Range bound oscillation in the price band of 18500-18800 is likely. Most of the index majors seen making a double top pattern is a concern.

On the Nifty hourly chart, massive negative divergence in RSI suggesting the benchmark index may remain stuck in the price band of 18500-18800. Staying cautious on rise is advised.

Nifty patterns on multiple periods suggesting; it ended the day on a nervous note. Being extremely overbought on daily, the Benchmark Index may see profit booking on rise. Massive resistance is placed around 18900 levels. Hence, staying cautious on rise is advised.

### Nifty Crucial Supports & Resistances-

**Supports- 18500, 18440 Resistances- 18730, 18800**

### Open Positional Calls-

T+15 INST POSITIONAL SELL-

| Fut Segment | ITC @ 350-355, TGT- 325, Closing SL- above 370

T+15 INST POSITIONAL SELL-

| Fut Segment | HDFC @ 2640-2660, TGT- 2520, Closing SL- above 2730

T+15 INST POSITIONAL SELL-

| Fut Segment | HDFC BANK @ 1620-1640, TGT- 1530, Closing SL- above 1680

T+15 INST POSITIONAL BUY-

| Cash Segment | PAGE IND @ 46500-45500, TGT- 49500, Closing SL- below 44000

T+15 INST POSITIONAL SELL-

| Fut Segment | SBIN @ 610-615, TGT- 575, Closing SL- above 635

T+15 INST POSITIONAL SELL-

| Fut Segment | CAN BANK @ 330-335, TGT- 295, Closing SL- above 355

T+15 INST POSITIONAL SELL-

| Fut Segment | M&M @ 1320-1340, TGT- 1230, Closing SL- above 1380

### Key Contents

Domestic News

### Page No.

4

## Nifty Intraday Chart



## Market in Retrospect

The Indian benchmark indices started on a marginally positive note and stayed flat through the trading day on Thursday.

Nifty index ended 0.26% higher at 18,609. The broader markets represented by the Nifty 500 Index ended 0.31% higher, ending at 15,911. Among the sectorial indices, Nifty PSU Bank was the top gainer gaining by 3.81%, followed by Nifty Bank was gaining by 1.16%. Nifty Pharma was the top loser losing by 1.10%.

AXIS Bank was the top gainer, gaining by 2.70%, followed by Indusind Bank and L&T which gaining by 2.25% & 2.06%. Sun Pharma was the top loser, losing by 3.63%, followed by Divi's Lab and Power Grid which losing by 1.52% & 1.47%.

## Market Turnover (In Crore) 08-12-2022

Name	Last	Previous
NSE Cash	51454.28	49474.39
NSE F&O	30927257.81	15186329.68
BSE Cash	5,378.46	3,316.17
BSE F&O	*NA	149.10

## FII Derivatives Flow (In Crore) 07-12-2022\*

Instrument	Purchase	Sale	Net
Index Future	1814.76	3033.17	1218.41
Index Option	1044803.95	1045840.53	1036.58
Stock Future	7710.56	8628.89	918.33
Stock Option	7468.41	7616.94	148.53

## Institutional Flow (In Crore) 08-12-2022

Institution	Purchase	Sale	Net
FII	8714.35	9846.02	1131.67
DII	6297.04	5524.75	772.29

## NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Axis Bank	2.70	3.93	17466047	6918974
Indusind Bank	2.25	1.44	3666432	2943524
Larsen & Toubro	2.06	3.02	3743754	2261643
Eicher Motors	1.92	3.35	862490	875627
Hindalco Industries	1.58	1.78	4902003	9476860

## NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
NTPC	0.87	1.07	4225180	8035962
TCS	0.89	3.60	1285619	1680435
Power Grid	1.47	1.85	8382330	8957218
Divi'S Laboratories	1.52	3.57	347880	317572
Sun Pharmaceutical	3.63	6.27	10021644	2146523

## Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>  
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

\*data not updated till 7 pm



## Sensex Intraday Chart



## Market in Detailed (Updated after 4:00 PM)

### Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	62570.68	160.00	0.26	1.13	2.52	4.65	6.40
Nifty	18609.35	48.85	0.26	1.08	2.49	4.35	6.24
BSE M Cap	26212.36	111.07	0.43	0.38	1.50	1.22	2.75
BSE S Cap	29855.79	96.00	0.32	0.51	1.92	1.29	3.72
Nifty MC 100	32503.95	195.65	0.61	0.68	2.45	1.46	5.00
BSE Auto	29633.65	35.08	0.12	2.26	3.03	2.17	18.38
BSE Capgoods	34952.62	498.19	1.45	2.39	4.80	4.88	22.98
BSE FMCG	16629.94	1.05	0.01	0.81	2.03	3.95	20.57
BSE Metal	20807.76	139.03	0.67	0.94	4.64	8.74	5.49
BSE Oil&Gas	20526.94	44.84	0.22	0.26	3.44	2.46	12.85
BSE Healthcare	23343.68	208.76	0.89	2.54	2.82	1.09	6.83
BSE Power	4585.59	25.72	0.56	1.72	6.26	11.09	28.33
BSE Realty	3618.35	31.39	0.86	1.04	2.90	3.33	8.76
BSE ConsDur	40748.67	61.16	0.15	2.13	2.90	4.88	6.21
BSE Bank	49652.21	517.34	1.05	0.64	3.66	7.27	17.78
BSE IT	30251.12	9.43	0.03	2.83	4.75	5.43	14.22

### Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	3.45	0.03	1.00	1.53	16.30	4.04	126.87
UK	3.06	0.02	0.59	1.23	13.80	2.70	295.10
Brazil	5.72	0.10	1.65	2.22	10.52	0.61	24.84
Japan	0.26	0.00	0.00	0.79	1.19	1.19	410.00
Australia	3.37	0.01	0.30	3.30	16.58	5.66	107.78
India	7.29	0.02	0.23	0.93	1.99	2.95	14.83
Switzerland	1.06	0.03	2.51	2.22	6.52	11.45	500.38
Germany	1.80	0.02	1.07	0.72	21.04	4.89	675.40

### Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	82.43	0.05	0.06	1.47	0.63	3.30	8.46
USD Index	105.23	0.13	0.12	0.48	4.02	4.08	9.73
YUAN	6.97	0.00	0.06	1.14	3.68	0.24	9.03
GBP	1.22	0.00	0.30	0.65	5.40	5.76	7.85
EUR	1.05	0.00	0.07	0.07	4.36	5.16	7.32
YEN	136.88	0.26	0.19	1.13	6.43	5.28	16.96

### Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	1373.00	33.00	2.46	1.33	1.25	16.55	59.89
Baltic Dirty	2095.00	17.00	0.80	7.30	12.82	47.95	171.73
SG Dubai HY	25.48	2.40	10.40	18.79	23.39	24.23	638.55

### Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	33597.92	1.58	0.00	2.87	1.32	5.74	6.03
Nasdaq	10958.55	56.34	0.51	4.44	3.22	7.62	30.58
S&P 500	3933.92	7.34	0.19	3.58	2.76	1.80	16.32
FTSE100	7484.90	4.07	0.05	0.97	2.45	3.07	2.02
CAC40	6643.02	17.65	0.26	1.64	3.13	8.44	5.30
DAX	14209.04	47.97	0.34	1.91	3.83	10.14	9.40
Mexico IPC	50725.96	294.68	0.58	1.86	0.32	9.60	0.65
Brazil Bovespa	109068.6	1120.02	1.02	3.04	6.11	0.77	0.90
Russian RTS	1099.63	0.61	0.06	2.14	3.81	11.17	31.82
Japan Nikkei	27574.43	111.97	0.40	2.31	0.51	2.27	4.01
Hang Seng	19450.23	635.41	3.38	3.81	18.90	0.45	19.81
Taiwan Index	14553.04	76.97	0.53	3.06	6.70	0.21	18.76
Shanghai Comp	3197.35	2.27	0.07	1.01	4.89	1.98	12.95
KOSPI	2371.08	11.73	0.49	4.39	2.20	0.55	21.74
Malaysia KLCI	1465.93	0.95	0.06	1.72	1.36	2.04	2.39
Jakarta Comp	6804.23	14.53	0.21	3.08	3.76	6.05	2.41
Philippine SE	6525.16	149.22	2.24	3.77	3.75	1.04	8.70
Thai Exch	1620.49	1.79	0.11	0.91	0.12	2.06	0.14

### Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	73.35	1.37	1.90	9.65	17.47	12.16	1.41
BRENT Crude	78.04	0.92	1.19	10.12	16.91	9.45	8.49
Natural Gas	5.87	0.15	2.53	12.91	10.06	28.40	42.50

### LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1785.97	0.35	0.02	0.95	4.29	4.53	0.16
Silver(\$/Ounce)	22.75	0.03	0.13	0.02	6.54	22.74	1.41
Aluminium	2452.50	24.76	1.00	0.20	5.59	10.25	6.98
Copper	8430.00	45.25	0.54	2.47	6.38	9.50	12.30
Zinc	3207.00	28.00	0.88	5.14	10.30	1.79	2.47
Lead	2196.25	10.25	0.46	0.66	7.57	15.53	0.03

### Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	161.70	1.50	0.94	2.44	1.49	25.38	31.90
Cotton	82.57	0.74	0.90	2.69	3.70	18.04	5.24
Sugar	19.72	0.24	1.23	0.51	3.79	11.29	6.48
Wheat	751.75	2.25	0.30	3.99	11.30	10.90	5.77
Soybean	1476.50	4.50	0.31	3.27	2.07	6.13	18.69

### **Hindustan Unilever to acquire stake in Oziva and Wellbeing Nutrition**

Hindustan Unilever (HUL) is investing in Zywie Ventures which sells plant-based supplement brand Oziva and Nutritionalab which owns nutritional products under Wellbeing to enter the health and wellness market worth Rs 30,000 crore. HUL will acquire 51% equity stake in Oziva for Rs264 crore in the first tranche while the balance 49% will be acquired at the end of three year period based on pre-agreed valuation, which it did not specify. In addition, HUL will buy 19.8% equity stake in Wellbeing Nutrition for about Rs 70 crore.

### **India government invests over Rs 5,000 cr more in SWAMIH Investment Fund I to help homebuyers**

The government of India has invested over Rs 5,000 crore in the SBICAP Ventures-backed SWAMIH Investment Fund I, set up under the Special Window for Affordable and Mid-Income Housing, taking its final close to Rs 15,530 crore. This is amongst the biggest corpus raised by any funds in India in the last few years. SWAMIH Investment Fund I is India's largest social impact fund aiming to provide priority debt financing for the completion of stressed, brownfield and RERA registered residential projects that fall in the affordable, mid-income.

### **India's power giant NTPC will turn to nuclear fleet in climate goal chase**

NTPC Ltd., India's top power producer, is planning to build a massive nuclear fleet that'll aid the nation's push to shift away from coal and curb emissions to hit net-zero by 2070. The state-run company aims to install 20 to 30 gigawatts of nuclear capacity by 2040, according to a person familiar with the plans, who requested anonymity to discuss the private proposals and said the target remains tentative. India currently has 22 operational reactors with about 6.8 gigawatts of capacity. NTPC is considering deploying small-scale modular reactors, known as SMRs, as part of the strategy, according to multiple people with knowledge of the company's plans. The producer has an overall power fleet of 70 gigawatts, of which more than 80% is coal-fired. The company will also keep pursuing larger projects in a joint venture with state-run Nuclear Power Corp. of India Ltd. — which currently operates all of India's atomic generation capacity — the people said. NTPC has assembled a 15-member team in Mumbai to drive its nuclear ambitions, according to one of the people.

### **JSP acquires debt-laden Monnet Power for Rs 410 cr**

Jindal Steel and Power (JSP) Limited has acquired debt-laden Monnet Power for Rs 410 crore through insolvency route, a company official said on Thursday. The transaction for the Odisha-based 1,050 megawatt power asset was completed, Kapil Mantri, head of strategy at JSP told PTI. The new asset will provide power to JSP's steel plant in Angul, which is in expansion mod.

### **US FDA issues import alert on Sun Pharma's Halol facility**

Sun Pharma the US Food and Drug Administration (USFDA) has imposed an import alert on its Halol manufacturing site in Gujarat, that bans future shipments of products from the facility to the US market, until resolution of regulatory compliance issues flagged by the regulatory agency. The USFDA, however, excluded 14 products from this import alert, subject to certain 'confidential' conditions.

### CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Tembo Global Industries Ltd	Cash dividend of INR1.20 effective 09-12-22
Kamdhenu Ltd	Corporate meeting effective 09-12-22
Avon Mercantile Ltd	Corporate meeting effective 09-12-22
Foods & Inns Ltd	Corporate meeting effective 09-12-22
Knowledge Marine & Engineering Works Ltd	Corporate meeting effective 09-12-22

### Domestic Events

- India Foreign Exchange Reserve for December 02, 2022.

### Global Events

- China Inflation for November 2022.



### Analyst Certification:

We /I, Jaydeb Dey Research Analyst(S) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

### Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document

to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at [www.nseindia.com](http://www.nseindia.com) and/or [www.bseindia.com](http://www.bseindia.com), [www.mcxindia.com](http://www.mcxindia.com) and/or [www.icex.com](http://www.icex.com).

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.



### Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

---

### Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

---

### Contact us:

**SMIFS Limited.** (<https://www.smifs.com/>)

### Compliance Officer:

**Sudipto Datta,**

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: [compliance@smifs.com](mailto:compliance@smifs.com)

---